Cannabis and Cancer: Peer-Reviewed Research Consensus

242 studies analyzedLast updated March 7, 2026

Overview

The research base for cannabis and cancer includes 242 peer-reviewed studies spanning 1975–2026. Of these, 13 provide strong evidence, including 5 meta-analyses and 10 randomized controlled trials. Key findings with strong support include: meta-analysis of 30 trials found cannabinoids significantly outperformed older anti-nausea drugs for chemotherapy, with nearly half of 1,138 patients preferring cannabinoids despite more side effects, and phase ii crossover trial found oral thc:cbd capsules nearly doubled complete response for refractory chemo nausea (25% vs 14%), with 83% of patients preferring cannabis to placebo despite more side effects. However, several findings remain debated, and the evidence is not uniform across all areas. Many studies have methodological limitations including small sample sizes, short follow-up periods, and reliance on self-reported data.

What the Research Shows

Findings supported by multiple peer-reviewed studies. Stronger evidence means more consistency across study types.

Meta-analysis of 30 trials found cannabinoids significantly outperformed older anti-nausea drugs for chemotherapy, with nearly half of 1,138 patients preferring cannabinoids despite more side effects

Strong Evidence
2 studies|Many included trials were from the 1980s-1990s and used outdated comparator drugs (neuroleptics rather than modern anti-emetics like ondansetron). Some individual trials had small samples. The increas

Phase II crossover trial found oral THC:CBD capsules nearly doubled complete response for refractory chemo nausea (25% vs 14%), with 83% of patients preferring cannabis to placebo despite more side effects

Strong Evidence
1 study|Small phase II sample. Self-titrated dosing introduces variability. The 31% rate of moderate-severe side effects (sedation, dizziness, disorientation) is significant and may limit practical use.

Where Scientists Disagree

Areas where research shows conflicting results or ongoing scientific debate.

In a landmark NEJM trial, oral THC prevented chemotherapy vomiting in 80% of completed courses versus 0% for placebo, with no vomiting during subjective highs

Moderate Evidence
37 studies|Small sample of 22 patients with only 20 evaluable. The abstract does not specify the THC dose. Crossover design means carryover effects are possible. Published in 1975, before modern antiemetic drugs

A 1981 critical review found THC showed promise against chemotherapy nausea but identified significant gaps in safety and pharmacological knowledge

Moderate Evidence
37 studies|The review itself acknowledged that the evidence base had significant deficiencies. As a review from 1981, it predates decades of subsequent antiemetic research including modern serotonin antagonists

In 214 cancer patients, THC and prochlorperazine were equally effective against chemotherapy nausea

Moderate Evidence
37 studies|Crossover design means each patient received both treatments, which may introduce carryover effects. The "unblinding" finding suggests the double-blind was not perfect, potentially biasing results. Th

A 1983 review found THC outperformed placebo and standard drugs for chemotherapy nausea, with effectiveness linked to the "high

Moderate Evidence
37 studies|Narrative review format means no systematic quality assessment of included studies. The correlation between "high" and efficacy could reflect unblinding rather than a true mechanistic link.

What We Still Don't Know

  • Only 10 randomized controlled trials exist out of 242 studies — most evidence is observational or from reviews.
  • Sex-specific differences in this area remain understudied.
  • Long-term prospective studies tracking outcomes over 5+ years are largely absent from the literature.
  • Research on diverse populations (different ages, ethnicities, and medical backgrounds) remains limited.

Evidence Breakdown

Distribution of study types in this research area. Higher-tier evidence (meta-analyses, RCTs) provides stronger conclusions.

Meta-Analyses & Systematic Reviews(Tier 1)
5 (2%)
Randomized Controlled Trials(Tier 2)
10 (4%)
Observational & Cohort(Tier 3-4)
52 (21%)
Reviews & Scoping(Tier 4)
95 (39%)
Case Reports & Animal(Tier 5)
6 (2%)
Other
74 (31%)

Key Studies

The most impactful research in this area.

Meta-Analysis of 30 Trials Found Cannabinoids More Effective Than Standard Anti-Nausea Drugs for Chemotherapy

This was one of the most comprehensive meta-analyses of cannabinoids for chemotherapy nausea at the time. The clear superiority over neuroleptic anti-emetics and overwhelming patient preference provided strong evidence for cannabinoids in this indication.

2008

Large-scale analysis found scientific support for medical cannabis in cancer treatment far outweighs opposition

Cannabis remains Schedule I in the US, complicating cancer research, yet this analysis suggests overwhelming scientific consensus already supports its therapeutic role in oncology.

2025

Cannabinoids prevented chemo nausea better than placebo but have not been tested against modern treatments

Despite decades of interest, almost all evidence predates modern antiemetic protocols, leaving a critical gap for current oncology practice.

2025

Meta-Analysis Finds Cannabis Use Associated with Lower Oral Cancer Risk

Given that cannabis smoke contains many of the same carcinogens as tobacco smoke, a protective association with oral cancer is counterintuitive and demands further investigation into potential anti-tumor mechanisms.

2025

Medicinal cannabis did not improve depression or anxiety in cancer patients but did help appetite

Many cancer patients use cannabis hoping it will help their mental health. This meta-analysis shows that while cannabis may benefit appetite, it does not appear to help with depression, anxiety, or stress in cancer, and higher THC doses may actually worsen anxiety.

2024

Oral THC/CBD capsules improved chemo nausea when standard anti-nausea drugs failed

This is one of the first rigorous trials of standardized oral THC:CBD for refractory chemotherapy nausea, a significant unmet need since many patients fail standard antiemetics.

2020

Research Timeline

How our understanding of this topic has evolved.

Pre-2000

14 studies published. Includes 3 RCTs.

2000–2009

15 studies published. Includes 1 meta-analyses, 2 strong-evidence studies.

2010–2014

7 studies published. Includes 1 RCTs.

2015–2019

40 studies published. Includes 2 strong-evidence studies.

2020–present

166 studies published. Includes 4 meta-analyses, 6 RCTs, 9 strong-evidence studies.

About This Consensus

This consensus synthesizes 242 peer-reviewed studies: 5 meta-analyses (2%), 10 randomized controlled trials (4%), 52 observational studies (21%), 95 reviews (39%), 6 case studies (2%), 74 other study types (31%). Studies span from the earliest available research through 2025. Evidence strength ratings reflect study design, sample size, and replication across multiple research groups.

This page synthesizes findings from 242 peer-reviewed studies. It is not medical advice. Always consult a healthcare provider for personal health decisions.